Coartemether (artemether and lumefantrin): An oral antimalarial drug

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 2, 2004, Pages 181-196

  Wernsdorfer, Walther H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Artemether; Coarremether; Lumefantrine; Malaria; Plasmodium falciparum; Plasmodium vivax

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; DESBUTYLBENFLUMETOL; DIHYDROARTEMISININ; DOXYCYCLINE; DRUG METABOLITE; FANSIDAR; HALOFANTRINE; KETOCONAZOLE; LENNON; MEFLOQUINE; NAPTHOQUINE; PRIMAQUINE; PYRIMETHAMINE; QUININE; QUININE DERIVATIVE; TRIMETHOPRIM; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; SESQUITERPENE;

ABDOMINAL PAIN; ANOREXIA; CARDIOTOXICITY; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCHEMICAL DETECTION; HEADACHE; HEART PROARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALARIA FALCIPARUM; MASS SPECTROMETRY; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PLASMODIUM FALCIPARUM; PRURITUS; REVIEW; SCHIZONT; TABLET FORMULATION; VOMITING; ANIMAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; ARTEMISININS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; ETHANOLAMINES; FLUORENES; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; SESQUITERPENES;

EID: 85047692367     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.2.181     Document Type: Review

References (69)

1. World Health Organization. WHO Expert Committee on Malaria, 20th report. WHO Tech. Rep. Ser. 892, 3 (2000).
2. Wernsdorfer G, Wernsdorfer W. Malaria at the turn from the 2nd to the 3rd millennium. Wien. Klin. Wochenschr. 115(Suppl. 3), 2-9 (2003).
3. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2, 209-218 (2002).
4. World Health Organization. The use of antimalarial drugs. Report of a WHO informal consultation. WHO Document WHO/CDS/RBM/2001.33. World Health Organization, Geneva, Switzerland, 47-50 (2001).
5. World Health Organization. Antimalarial drug combination therapy. Report of a WHO technical consultation. WHO Document WHO/CDS/RBM/2001.35. World Health Organization, Geneva, Switzerland, 6-28 (2001).
6. Krudsood S, Chalermut K, Pengruksa C et al. Comparative clinical trial of two fixed combinations dihydroartemisinin-naphthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian J. Trop. Med. Public Health 34, 316-321 (2003).
7. van Vugt M, Looareesuwan S, Wilairatana P et al. Artemether-lumefantrine for the treatment of multidrug resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94, 545-548 (2000).
8. Skelton-Stroud P, Mull R. Positioning, labeling and medical information control of co-artemether tablets (CPG 56697): a fixed novel combination of artemether and benflumetol. Novartis Co-Artemether International Development Team. Med. Trop. 53 (Suppl. 3), 77-81 (1998).
9. Harder A, Greif G, Haberkorn A. Chemotherapeutic approaches to protozoa: haemosporina - current level of knowledge and outlook. Parasitol. Res. 87, 781-784 (2001).
10. China Co-operative Research Group on Qinghaosu and its Derivatives as Antimalarials. The chemistry and synthesis of Qinghaosu derivatives. J. Tradit. Chin. Med. 2, 3-8 (1982).
11. World Health Organization. Practical chemotherapy of malaria. Report of a WHO Scientific Group. WHO Tech. Rep. Ser. 805. 124-126 (1990).
12. Zhong JX, Deng RX, Wang J, Zheng QT, Jiao KF. Crystal and molecular structure of the antimalarial agent α -(dibutylaminomethyl)-2, 7-dichloro-9-(p-chlorobenzylidene -4-fluorenemethanol (benflumetol). Yao Xue Xue Bao 32, 824-829 (1997).
13. Wernsdorfer WH, Landgraf B, Kilimali VA, Wernsdorfer G. Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa. Acta Tropica 70, 9-15 (1998).
14. Navaratnam V, Mansor SM, Chin LK, Mordi MN, Asokan M, Nair NK. Determination of artemether and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. J. Chromatogr. 699, 289-294 (1995).
15. Souppart C, Gauduchau N, Sandrenan N, Richard F. Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 774, 195-202 (2002).
16. Zeng MY, Lu ZL, Yang SC et al. Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr. B. Biomed. Appl. 681, 299-306 (1996).
17. Mansor SM, Navaratnam V, Yahaya N, Nair NK, Wernsdorfer WH, Degen PH. Determination of a new antimalarial drug, benflumetol, in blood plasma by high-performance liquid chromatography. J. Chromatogr. 682, 321-325 (1996).
18. Chimanuka B, Francois G, Timperman G et al. A comparison of the stage-specific efficacy of chloroquine, artemether and dioncophylline B against the rodent malaria parasite Plasmodium chabaudi chabaudi in vivo. Parasitol. Res. 87, 795-803 (2001).
19. Messori L, Piccioli F, Eitler B, Bergonzi MC, Bilia AR, Vincieri FF. Spectrophotometric and ESI-MS/HPLC studies reveal a common mechanism for the reaction of various artemisinin analogues with hemin. Bioorg. Me. Chem. Lett. 13, 4055-4057 (2003).
20. von Seidlein L, Bojang K, Jones P et al. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am. J. Trop. Med. Hyg. 58, 638-644 (1998).
21. Wernsdorfer WH, Wernsdorfer G, Prajakwong S, Woitsch B, Zatloukal C, Kollaritsch H. Activity correlation between artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum from Thailand. Mitteilungen der Oesterreichischen Gesellschaft fuer Tropenmedizin und Parasitologie 22, 87-93 (2000).
22. Zatloukal C, Woitsch B, Noedl H, Prajakwong S, Wernsdorfer G, Wernsdorfer WH. Longitudinale Beobachtungen über die Artemisininempfindlichkeit von Plasmodium falciparum in Thailand. (Longitudinal observations on the sensitivity of Plasmodium falciparum to artemisinin in Thailand) Mitteilungen der Oesterreichischen Gesellschaft fuer Tropenmedizin und Parasitologie 20, 165-170 (1998).
23. Woitsch B, Prajakwong S, Wernsdorfer G, Wiedermann G, Zatloukal C, Wernsdorfer WH. In vitro Untersuchungen ueber die Artemisininempfindlichkeit von Plasmodium falciparum in Mae Hong Son, Thailand, 1994-1999. (In vitro studies of the sensitivity to artemisinin in Plasmodium falciparum from Mae Hong Son, Thailand, in 1994-1999) Mitteilungen der Oesterreichischen Gesellschaft für Tropenmedizin und Parasitologie 22, 95-102 (2000).
24. Brockman A, Price RN, van Vugt M et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during 5 years of extensive use of artesunate-mefloquine. Trans. R. Soc. Trop. Med. Hyg. 94, 537-544 (2000).
25. Randrianarivelojosia M, Raharimalala LA, Randrianasolo L et al. Madagascan isolates of Plasmodium falciparum showing low sensitivity to artemether in vitro. Ann. Trop. Med. Parasitol. 95, 237-243 (2001).
26. Noedl H, Prajakwong S, Wiedermann G, Kollaritsch H, Wernsdorfer G, Wernsdorfer WH. Benflumetol: in vitro Sensibilitaet von Plasmodium falciparum in Thailand. (Benflumetol: in vitro sensitivity of Plasmodium falciparum in Thailand) Mitteilungen der Oesterreichischen Gesellschaft fuer Tropenmedizin und Parasitologie 20, 171-176 (1998).
27. Basco LK, Bickii J, Ringwald P. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Antimicrob. Agents Chemother. 42, 2347-2351 (1998).
28. Pradines B, Tall A, Fusai T et al. In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob. Agents Chemother. 43, 418-420 (1999).
29. Lefèvre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Clin. Drug Invest. 18, 467-480 (1999).
30. Noedl H, Allmendinger T, Prajakwong S, Wernsdorfer G, Wernsdorfer WH. Desbutyl-benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand. Antimicrob. Agents Chemother. 45, 2106-2109 (2001).
31. Oumaporn T, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J, Wernsdorfer WH. An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine. Acta Tropica 83, 49-61 (2002).
32. Lux D, Prajakwong S, Kollaritsch H, Wernsdorfer G, Wernsdorfer WH. In vitro sensitivity testing of Plasmodium vivax: response to lumefantrine and chloroquine in northwestern Thailand. Wien. Klin. Wochenschrift 115(Suppl.3), 50-54 (2003).
33. Alin H, Bjorkman A, Wernsdorfer WH. Synergism of benflumetol and artemether in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 61, 439-445 (1999).
34. Wernsdorfer WH, Noedl H. Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr. Opin. Infect. Dis. 16, 553-558 (2003).
35. Tanariya P, Tippawangkoso P, Karbwang J, Na-Bangchang K, Wernsdorfer WH. In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether. Br. J. Clin. Pharmacol. 49, 437-444 (2000).
36. ter Kuile FO, Luxemburger F, Nosten F et al. Predictors of mefloquine treatment failure: a prospective study in 1590 patients with uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 89, 660-664 (1995).
37. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37, 105-125 (1999).
38. Go ML, Li QT. Interaction of the antimalarial agents halofantrine and lumefantrine with lipid bilayers. Chem. Pharm. Bull. 51, 241-246 (2003).
39. von Seidlein L, Jaffar S, Greenwood B. Prolongation of the QTc interval in African children treated for falciparum malaria. Am. J. Trop. Med. Hyg. 56, 494-497 (1997).
40. van Vugt M, Ezzet, F., Nosten F et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am. J. Trop. Med. Hyg. 61, 964-967 (1999).
41. Bindschedler M, Lefèvre G, Degen P, Sioufi A. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. Am. J. Trop. Med. Hyg. 66, 295-300 (2002).
42. Bindschedler M, Lefèvre G, Ezzet F, Schaeffer N, Meyer I, Thomsen MS. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur. J. Clin. Pharmacol. 56, 375-381 (2000).
43. + currents by antimalarial drugs in stably transfected HEK293 cells. Eur. J. Pharmacol. 484(1), 41-48 (2004).
44. Colussi D, Parisot C, Leagay F, Lefèvre G. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur. J. Pharmaceut. Sci. 9, 9-16 (1999).
45. van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int. J. Antimicrob. Agents 12, 151-158 (1999).
46. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet. 40, 343-373 (2001).
47. Lefèvre G, Looareesuwan S, Treeprasertsuk S et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 64, 247-256(2001).
48. Na-Bangchang K, Karbwang J, Tasanor U, Thanavibul A, Farkad E, Mull R. Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. Int. J. Clin. Pharmacol. Res. 19, 41-46 (1999).
49. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether and benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46, 553-561 (1998).
50. Lefèvre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen MS. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur. J. Pharmaceut. Sci. 10, 141-151 (2000).
51. Lefèvre G, Carpenter P, Souppart C et al., Interaction trial between artemether-lumefantrine (Riamet®) and quinine in healthy subjects. J. Clin. Pharmacol. 42, 1147-1158 (2002).
52. Lefèvre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br. J. Clin. Pharmacol. 54, 485-492 (2002).
53. Jiao X, Liu GY, Shan CO et al. Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria. Southeast Asian J. Trop. Med. Public Health 28, 476-481 (1977).
54. Sun ZW, Shan CQ, Li GF et al. Clinical comparative trial of coartemether and benflumetol (two formulations) in the treatment of falciparum malaria. Zhongguo J. Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 18, 159-161 (2000).
55. Kshirsagar NA, Gogtay NJ, Moorthy NS et al. A randomized double-blind, parallel-group, comparative safety and efficacy trial of oral coartemether versus oral chloroquine in die treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am. J. Trop. Med. Hyg. 62, 402-408 (2000).
56. van Agtmael M, Bouchaud O, Malvy D et al. The comparative efficacy and tolerability of CGP 56697 (artemether and lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travelers returning from the tropics to The Netherlands and France. Int. J. Antimicrob. Agents 12, 159-169 (1999).
57. Looareesuwan S, Wilairatana P, Chokejindachai W et al. A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 60, 238-243 (1999).
58. van Vugt M, Brockman A, Gemperli B et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug resistant falciparum. Antimicrob. Agents Chemother. 42, 135-139 (1998).
59. van Vugt M, Looareesuwan S, Wilairatana P et al. Artemether-lumefantrine for the treatment of multidrug resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94, 545-548 (2000).
60. van Vugt M, Wilairatana P, Gemperli B et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 60, 936-942 (1999).
61. von Seidlein L, Jaffar S, Pinder M et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J. Infect. Dis. 176, 1113-1116 (1997).
62. Hatz C, Abdulla S, Mull R et al. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Trop. Med. Int. Health 3, 498-504 (1998).
63. Irion A, Felger I, Abdulla S et al. Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56697 and chloroquine in Tanzanian children. Trop. Med. Int. Health 3, 490-497 (1998).
64. Omari AA, Preston C, Garner P. Artemether-lumefantrine for treating uncomplicated falciparum malaria. Cochrane Database Syst. Rev. CD003125 (2003).
65. Li X, Li C, Che L et al. Observation on efficacy of artemether compound against vivax malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 17, 175-177 (1999).
66. Brewer TG, Peggins JO, Grate SJ et al. Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg. 88(Suppl.1), 33-36 (1994).
67. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans. R. Soc. Trop. Med. Hyg. 94, 419-424 (2000).
68. McGready R, Cho T, Keo NM et al. Artemisinin antimalarials in pregnancy: a prospective study of 539 episodes of multidrug resistant Plasmodium falciparum. Clin. Infect. Dis. 33, 2009-2016 (2001).
69. Wernsdorfer WH. Epidemiology of drug resistance in malaria. Acta Tropica 56, 143-156 (1994).